{"id":"NCT01939197","sponsor":"AbbVie","briefTitle":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection","officialTitle":"A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2013-08-30","primaryCompletion":"2016-07-21","completion":"2016-10-25","firstPosted":"2013-09-11","resultsPosted":"2017-11-17","lastUpdate":"2021-07-12"},"enrollment":318,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus Infection","Human Immunodeficiency Virus Infection","Chronic Hepatitis C","Compensated Cirrhosis and Non-cirrhotics"],"interventions":[{"type":"DRUG","name":"ABT-450/r/ABT-267","otherNames":["ombitasvir/paritaprevir/ritonavir","ombitasvir also known as ABT-267","paritaprevir also known as ABT-450"]},{"type":"DRUG","name":"ABT-333","otherNames":["Dasabuvir"]},{"type":"DRUG","name":"ribavirin","otherNames":[]}],"arms":[{"label":"ARM A","type":"EXPERIMENTAL"},{"label":"ARM B","type":"EXPERIMENTAL"},{"label":"ARM C","type":"EXPERIMENTAL"},{"label":"ARM D","type":"EXPERIMENTAL"},{"label":"ARM E","type":"EXPERIMENTAL"},{"label":"ARM F","type":"EXPERIMENTAL"},{"label":"ARM G","type":"EXPERIMENTAL"},{"label":"ARM H","type":"EXPERIMENTAL"},{"label":"ARM I","type":"EXPERIMENTAL"},{"label":"ARM J","type":"EXPERIMENTAL"},{"label":"ARM K","type":"EXPERIMENTAL"},{"label":"ARM L","type":"EXPERIMENTAL"}],"summary":"The primary objectives of this study are to assess the safety of ABT-450/r/ABT-267 with and without ABT-333 coadministered with and without ribavirin (RBV) for 12 and 24 weeks in HCV GT1- or 4-infected participants with HIV-1 coinfection and to evaluate the percentage of subjects achieving HCV ribonucleic acid (RNA) \\< lower limit of quantification (LLOQ) 12 weeks following treatment.","primaryOutcome":{"measure":"Percentage of Participants in GT1 Analysis Group 1 in Part 2 Achieving Sustained Virologic Response 12 Weeks Post-Treatment (SVR12)","timeFrame":"12 weeks after the last actual dose of study drug","effectByArm":[{"arm":"Part 2: GT1 Analysis Group","deltaMin":97,"sd":null}],"pValues":[{"comp":"OG000","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25706092","28412293","27919899","26743093"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":31},"commonTop":["FATIGUE","NAUSEA","HEADACHE","INSOMNIA","DIARRHOEA"]}}